last updated 2013-11-14 11:37:54
Full Page Link: http://www.aimlisting.co.uk/index.php/aim/fullcompany/AVCT
|Country of Incorporation:||United Kingdom|
|Region:||Yorkshire & North East|
|Sector||Pharmaceuticals & Biotechnology|
|Sub Sector||Pharmaceuticals & Biotechnology|
|Nomad:||Grant Thornton UK LLP|
|Advisor / Broker:||XCAP Securities PLC|
Unit 651, Street 5, Thorp Arch Estate, Wetherby, North Yorkshire
|Post Code:||LS23 7FZ|
|Tel:||+44 (0) 844 414 0452|
Low risk, high growth healthcare technology business at inflexion point
Avacta Group plc, a world leading, UK-based healthcare equipment and instrumentation business, provides innovative, high value proprietary technologies and services to the life sciences/healthcare sector through two operating divisions:
Avacta Analytical provides high-end analytical instrumentation and services to the biopharmaceutical sector, expected to be a $200bn revenues market by 2013 and the fastest growing part of the pharmaceutical industry. The Company’s technologies are aimed at reducing the risks and expense associated with biological drug development and thereby reducing the final cost of drugs to patients. The Company’s lead analytical instrument, Optim, is distributed through Pall Corporation in the US, Isogen Life Sciences in Europe, Cold Spring Biotech Corp in China and Taiwan and DKSH in Japan. Avacta sells Optim directly in the UK.
Avacta Animal Health provides diagnostic products and services for the $1.5bn global veterinary diagnostics market. Its aim is to equip veterinary professionals with high quality animal health and well-being information, through point of care diagnostics, reagents and testing kits and laboratory based testing. Avacta’s AX-1 point of care immunoassay system is aimed at providing the veterinarian with rapid blood test results in the clinic. The initial range of tests launched with the AX-1 relates to Avacta’s world leading allergy testing brand Sensitest®. Avacta is currently developing further assays for the AX-1 system to diagnose other diseases in companion animals. Longer term this technology will be transferred into the human clinical diagnostics market.
Company Documents - click to read more
Advisers - click to read more
Directors - click to read more
Related AIM News
WANT TO SHOW MORE INFORMATION ABOUT YOUR AIM COMPANY - UPGRADE YOUR PROFILE TO ADVANCED - CLICK HERE TO UPGRADE.
If you believe any information on the above company to be incorrect please contact our admin department immediately as we wish to ensure the information on this website is up to date. Click here for contact details.